{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:53:31Z","timestamp":1791356011020,"version":"4.3.1"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2023\/13622-1"],"award-info":[{"award-number":["2023\/13622-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004809","name":"Financiadora de Estudos e Projetos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jsbmb.2026.107101","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:09:58Z","timestamp":1786374598000},"page":"107101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring the putative role of EGFR in prostate cancer: Interactions with androgen and estrogen receptors"],"prefix":"10.1016","volume":"265","author":[{"given":"G.M.","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.R.M.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.G.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ceb.2007.02.008","article-title":"The EGF receptor family: spearheading a merger of signaling and therapeutics","volume":"19","author":"Bublil","year":"2007","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jsbmb.2026.107101_bib3","first-page":"315","article-title":"The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4","volume":"114","author":"Earp","year":"2003","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.jsbmb.2026.107101_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.pharmtox.44.101802.121440","article-title":"ErbB receptors: directing key signaling networks throughout life","volume":"44","author":"Holbro","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4-5","key":"10.1016\/j.jsbmb.2026.107101_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert. Opin. Ther. Targets"},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107101_bib6","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1091\/mbc.10.8.2493","volume":"10","author":"Dent","year":"1999","journal-title":"Mol. Biol. Cell."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.jsbmb.2026.107101_bib8","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF receptor ligands: recent advances","author":"Singh","year":"2016","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188789","article-title":"Can EGFR be a therapeutic target in breast cancer?","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107101_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/pros.70187","article-title":"Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta-Analysis of a Potential Therapeutic Target","volume":"86","author":"Luk","year":"2026","journal-title":"Prostate"},{"issue":"22","key":"10.1016\/j.jsbmb.2026.107101_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI189900","article-title":"Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition","volume":"135","author":"Wilkinson","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11033-025-11202-x","article-title":"HER2 as a molecular trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks","volume":"53","author":"Mukherjee","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jsbmb.2026.107101_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/curroncol33020091","article-title":"Historical Perspective of HER2 Testing and Treatment in Prostate Cancer","volume":"33","author":"Zamalloa","year":"2026","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107101_bib15","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/138161213804547222","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer","volume":"19","author":"Galvani","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"18","key":"10.1016\/j.jsbmb.2026.107101_bib17","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.yexcr.2011.08.023","article-title":"Epidermal growth factor receptor reactivation induced by E-prostanoid-3 receptor- and tumor necrosis factor-alpha-converting enzyme-dependent feedback exaggerates interleukin-8 production in airway cancer (NCI-H292) cells","volume":"317","author":"Kim","year":"2011","journal-title":"Exp. Cell. Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107101_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13543784.2024.2349287","article-title":"Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy","volume":"33","author":"Gonz\u00e1lez","year":"2024","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.annonc.2019.10.007","article-title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives","volume":"31","author":"Martinelli","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-022-01646-1","article-title":"A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer","volume":"21","author":"Schinke","year":"2022","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jcmgh.2023.02.003","article-title":"EGFR Reloaded: Finding New Ways to Shape Pancreatic Cancer Epigenome","volume":"15","author":"LaRue","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188827","article-title":"EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy","volume":"1878","author":"Kang","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/BST20191055","article-title":"Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis","volume":"48","author":"Lev","year":"2020","journal-title":"Biochem. Soc. Trans."},{"issue":"10087","key":"10.1016\/j.jsbmb.2026.107101_bib25","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2026.107101_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1394997","article-title":"Targeting the epidermal growth factor receptor (EGFR\/ErbB) for the potential treatment of renal pathologies","volume":"15","author":"Tawengi","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"23","key":"10.1016\/j.jsbmb.2026.107101_bib27","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.3390\/ijms222312828","article-title":"The Role of EREG\/EGFR Pathway in Tumor Progression","volume":"22","author":"Cheng","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107101_bib28","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3390\/cells9081887","article-title":"Role of EGFR in the Nervous System","volume":"9","author":"Romano","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jsbmb.2026.107101_bib29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fcell.2020.00776","article-title":"Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains","volume":"8","author":"Hajdu","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107101_bib30","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bpj.2020.10.008","article-title":"Autophosphorylation of EGFR at Y954 Facilitated Homodimerization and Enhanced Downstream Signals","volume":"119","author":"Thirukkumaran","year":"2020","journal-title":"Biophys. J."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107101_bib31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.bpj.2017.06.029","article-title":"Quantifying the Interaction between EGFR Dimers and Grb2 in Live Cells","volume":"113","author":"Del Piccolo","year":"2017","journal-title":"Biophys. J."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107101_bib32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/pharmrev.123.000906","article-title":"Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor","volume":"75","author":"Zhang","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/biom14030259","article-title":"The Configuration of GRB2 in Protein Interaction and Signal Transduction","volume":"14","author":"Wang","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jsbmb.2026.107101_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2142\/biophysico.bppb-v18.001","article-title":"Biphasic spatiotemporal regulation of GRB2 dynamics by p52SHC for transient RAS activation","volume":"18","author":"Yoshizawa","year":"2021","journal-title":"Biophys. Phys."},{"issue":"19","key":"10.1016\/j.jsbmb.2026.107101_bib35","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1091\/mbc.E21-01-0007","article-title":"p52Shc regulates the sustainability of ERK activation in a RAF-independent manner","volume":"32","author":"Yoshizawa","year":"2021","journal-title":"Mol. Biol. Cell."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials","volume":"10","author":"Song","year":"2022","journal-title":"Genes. Dis."},{"key":"10.1016\/j.jsbmb.2026.107101_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"issue":"48","key":"10.1016\/j.jsbmb.2026.107101_bib39","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41388-019-0950-z","article-title":"PKC\u03b1 is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation","volume":"38","author":"Salama","year":"2019","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107101_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109181","article-title":"PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR","volume":"35","author":"Ghosh","year":"2021","journal-title":"Cell. Rep."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41419-022-04941-3","article-title":"Blocking STAT3 signaling augments MEK\/ERK inhibitor efficacy in esophageal squamous cell carcinoma","volume":"13","author":"Zheng","year":"2022","journal-title":"Cell. Death Dis."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107101_bib42","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1541-7786.MCR-18-0125","article-title":"EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival","volume":"16","author":"Roos","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107101_bib43","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"22","key":"10.1016\/j.jsbmb.2026.107101_bib45","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1091\/mbc.E15-05-0269","article-title":"Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer","volume":"26","author":"Valley","year":"2015","journal-title":"Mol. Biol. Cell."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5483\/BMBRep.2020.53.3.025","article-title":"Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective","volume":"53","author":"Cho","year":"2020","journal-title":"BMB Rep."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.5306\/wjco.v5.i5.806","article-title":"Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants","volume":"5","author":"Chung","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib48","first-page":"2742","article-title":"Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants","volume":"15","author":"Hayes","year":"2024"},{"key":"10.1016\/j.jsbmb.2026.107101_bib49","first-page":"518","article-title":"Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias","volume":"602","author":"Hu","year":"2022"},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib51","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal Therapy for Prostate Cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107101_bib54","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107101_bib55","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"6 Pt 1","key":"10.1016\/j.jsbmb.2026.107101_bib56","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0022-5347(17)32335-2","article-title":"Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues","volume":"152","author":"Cohen","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41241-018-0069-5","article-title":"Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma","volume":"39","author":"Hashmi","year":"2019","journal-title":"Appl. Cancer Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/modpathol.2010.45","article-title":"Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas","volume":"23","author":"de Muga","year":"2010","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107101_bib59","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41416-020-01052-8","article-title":"EGFR as a stable marker of prostate cancer dissemination to bones","volume":"123","author":"Nasta\u0142y","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/ol.2012.996","article-title":"Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors","volume":"5","author":"Carlsson","year":"2013","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107101_bib61","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1464-410X.2003.04503.x","article-title":"ErbB receptors: possible therapeutic targets in prostate cancer?","volume":"92","author":"Ratan","year":"2003","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pros.10245","article-title":"ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002","volume":"56","author":"T\u00f8rring","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2026.107101_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0304-3835(98)00256-0","article-title":"Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate","volume":"134","author":"Kumar","year":"1998","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jsbmb.2026.107101_bib64","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-5347(17)37287-7","article-title":"p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate","volume":"147","author":"Mellon","year":"1992","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib65","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/sj.onc.1210983","article-title":"Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations","volume":"27","author":"Cai","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107101_bib66","first-page":"951","article-title":"Expression of transforming growth factor-alpha and the epidermal growth factor receptor in the benign and malignant human prostate","volume":"151","author":"Cohen","year":"1994","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00925693","article-title":"Expression of mRNA for epidermal growth factor, transforming growth factor-alpha, and their receptor in human prostate tissue and cell lines","volume":"126","author":"Ching","year":"1993","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jsbmb.2026.107101_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","article-title":"HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone","volume":"77","author":"Day","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","article-title":"A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer","volume":"31","author":"Whang","year":"2013","journal-title":"Urol. Oncol."},{"issue":"21","key":"10.1016\/j.jsbmb.2026.107101_bib70","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1158\/1078-0432.CCR-12-2219","article-title":"Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08\/07)","volume":"18","author":"Cathomas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107101_bib71","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/cancers17172804","article-title":"Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance","volume":"17","author":"Leite","year":"2025","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.jsbmb.2026.107101_bib72","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.3390\/jcm13216391","article-title":"EGFR-Targeted Therapies: A Literature Review","volume":"13","author":"Sha","year":"2024","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/JME-07-0021","article-title":"Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation","volume":"39","author":"L\u00e9otoing","year":"2007","journal-title":"J. Mol. Endocrinol."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107101_bib74","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/sj.bjc.6605376","article-title":"Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth","volume":"101","author":"Traish","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107101_bib75","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pros.2990120108","article-title":"Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumour cell","volume":"12","author":"Schuurmans","year":"1988","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2026.107101_bib76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0303-7207(88)90124-4","article-title":"Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP)","volume":"60","author":"Schuurmans","year":"1988","journal-title":"Mol. Cell. Endocrinol."},{"issue":"20","key":"10.1016\/j.jsbmb.2026.107101_bib77","first-page":"4640","article-title":"Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor","volume":"58","author":"Hobisch","year":"1998","journal-title":"Cancer Res."},{"issue":"8-9","key":"10.1016\/j.jsbmb.2026.107101_bib78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.steroids.2004.05.011","article-title":"The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells","volume":"69","author":"Bonaccorsi","year":"2004","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib79","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijc.20362","article-title":"EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR)","volume":"112","author":"Bonaccorsi","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107101_bib80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2026.107101_bib81","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107101_bib83","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/0008-5472.CAN-08-3760","article-title":"Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines","volume":"69","author":"Pignon","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107101_bib84","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B","article-title":"Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma","volume":"82","author":"Myers","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107101_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0303-7207(02)00374-X","article-title":"Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines","volume":"198","author":"Orio","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib86","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/JME-07-0021","article-title":"Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation","volume":"39","author":"Leotoing","year":"2007","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib87","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2353\/ajpath.2008.071054","article-title":"Stat3 promotes metastatic progression of prostate cancer","volume":"172","author":"Abdulghani","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib88","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mce.2007.02.006","article-title":"An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells","volume":"270","author":"Aaronson","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107101_bib89","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","article-title":"Androgen receptor and growth factor signaling cross-talk in prostate cancer cells","volume":"15","author":"Zhu","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"issue":"37","key":"10.1016\/j.jsbmb.2026.107101_bib90","doi-asserted-by":"crossref","first-page":"28787","DOI":"10.1074\/jbc.M110.134064","article-title":"Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells","volume":"285","author":"Sen","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib91","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bph.12307","article-title":"A novel androgen signalling pathway uses dihydrotestosterone, but not testosterone, to activate the EGF receptor signalling cascade in prostate stromal cells","volume":"170","author":"Oliver","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib92","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.biocel.2008.07.004","article-title":"A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells","volume":"41","author":"Recchia","year":"2009","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib93","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cellsig.2016.01.013","article-title":"The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance","volume":"28","author":"Zarif","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jsbmb.2026.107101_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.febslet.2004.06.088","article-title":"Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer","volume":"571","author":"Montano","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jsbmb.2026.107101_bib95","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/carcin\/bgi324","article-title":"Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene","volume":"27","author":"Li","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jsbmb.2026.107101_bib96","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1074\/jbc.M307649200","article-title":"Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer","volume":"279","author":"Gregory","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2026.107101_bib97","doi-asserted-by":"crossref","first-page":"20989","DOI":"10.1074\/jbc.M802392200","article-title":"Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer","volume":"283","author":"Ponguta","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2026.107101_bib98","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/6495","article-title":"A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase","volume":"5","author":"Craft","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsbmb.2026.107101_bib99","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1073\/pnas.96.10.5458","article-title":"From HER2\/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells","volume":"96","author":"Yeh","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jsbmb.2026.107101_bib100","first-page":"2643","article-title":"HER-2\/neu (p185neu) protein expression in the natural or treated history of prostate cancer","volume":"7","author":"Osman","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107101_bib101","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107101_bib102","first-page":"545","article-title":"Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms","volume":"1","author":"Scher","year":"1995","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107101_bib103","first-page":"3438","article-title":"Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer","volume":"8","author":"Di Lorenzo","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.jsbmb.2026.107101_bib104","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/pros.20460","article-title":"Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence","volume":"66","author":"Shah","year":"2006","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0960-0760(01)00190-X","article-title":"Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer","volume":"80","author":"Filardo","year":"2002","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107101_bib106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1210\/mend.16.1.0758","article-title":"Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis","volume":"16","author":"Filardo","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2026.107101_bib107","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.matbio.2013.09.002","article-title":"Cross-talk between estradiol receptor and EGFR\/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans","volume":"35","author":"Skandalis","year":"2014","journal-title":"Matrix Biol."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib108","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/me.2002-0368","article-title":"Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor","volume":"17","author":"Levin","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-005-9070-2","article-title":"Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth","volume":"96","author":"Britton","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1385\/ENDO:16:2:073","article-title":"Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor","volume":"16","author":"M\u00e1rquez","year":"2001","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107101_bib111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopha.2003.09.006","article-title":"Estrogen\/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies","volume":"57","author":"Lichtner","year":"2003","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107101_bib112","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr. Rev."},{"issue":"18","key":"10.1016\/j.jsbmb.2026.107101_bib113","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.3390\/cancers15184653","article-title":"Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function","volume":"15","author":"Belluti","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107101_bib114","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2013.06.010","article-title":"Nuclear EGFR as a molecular target in cancer","volume":"108","author":"Brand","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"13","key":"10.1016\/j.jsbmb.2026.107101_bib115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2011269118","article-title":"Estrogen receptor \u03b2 and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate","volume":"118","author":"Wu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107101_bib116","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170809","article-title":"The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression","volume":"134","author":"Lafront","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2026.107101_bib117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.steroids.2015.12.021","article-title":"Expression and regulation of the estrogen receptors in PC-3 human prostate cancer cells","volume":"107","author":"Pisolato","year":"2016","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107101_bib118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mce.2018.12.015","article-title":"Estrogen receptors localization and signaling pathways in DU-145 human prostate cancer cells","volume":"483","author":"Souza","year":"2019","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:29:30Z","timestamp":1791354570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076026001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":118,"alternative-id":["S0960076026001676"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107101","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the putative role of EGFR in prostate cancer: Interactions with androgen and estrogen receptors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107101"}}